An immunological and transcriptomics approach on differential modulation of NK cells in multiple sclerosis patients under interferon-beta 1 and fingolimod therapy

Acar N. P. , Tuncer A., Ozkazanc D., Ozbay F. G. , KARAOSMANOĞLU B. , Goksen S., ...More

JOURNAL OF NEUROIMMUNOLOGY, vol.347, 2020 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 347
  • Publication Date: 2020
  • Doi Number: 10.1016/j.jneuroim.2020.577353


This study aims to compare NK cells obtained from multiple sclerosis (MS) patients receiving interferon-beta 1 and fingolimod therapies. Fingolimod reduced the CD56(bright) NK cell subset. The remaining CD56(dim) NK cells displayed NKG2D, NKp46, CD107a, and IFN-gamma levels similar to those from the patients under interferon-beta 1 therapy. Alternatively, comparative transcriptomics and pathway analyses revealed significant distinctions between two therapy modalities. Molecular signature of the CD56(dim) NK cells from fingolimod-treated MS patients was closely associated to those from healthy subjects. The basic assets of NK cells were modestly influenced by interferon-beta 1 and fingolimod, however transcriptomics showed profound alterations in NK responses.